Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Editing: Rewriting The Code

This article was originally published in Start Up

Executive Summary

Gene editing technologies, which enable knockout or modification of specific genes, could get first use in modifying T cells to fight cancer and HIV, but its long-term potential to control gene expression in vivo has sparked Series A financings of three start-ups in the past 18 months.

You may also be interested in...



Deal-Making, Financing Coalesce Around Promising CAR-T Space In Cancer

A huge IPO for Kite Pharma and two massive venture rounds for Juno Therapeutics have those two newer companies out in front in CAR therapeutics, but bigger, more established firms like Novartis, Pfizer and Celgene are in the game, while other companies, like biotech Bellicum, are looking to get in. Can Kite and Juno stay ahead and stand alone?

Sangamo On A Roll, Clarifies Timelines And Catalysts, Takes On CRISPR

Sangamo used 2013 to progress its pipeline, to raise money and to acquire a company. The momentum carried into the first quarter of 2014 with the Biogen partnership and a jump in share price that suggested that investors finally may have bought into the gene therapy company’s unique story.

Homology Medicines Inc.

Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel